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Pelvic inﬂammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia
trachomatis antibodies as a surrogate marker of chlamydial pelvic inﬂammatory disease. Women with ovarian cancer (n = 521)
and population-based controls (n = 766) were tested. IgG antibodies to serovar D of chlamydia elementary bodies (EBs) were
detected using an ELISA assay. The odds of having ovarian cancer among women with the highest titers (≥0.40 OD units) were 0.6
(95% CI 0.4–0.9). These data do not support our earlier ﬁnding of elevated titers for antibodies to C. trachomatis among women
with ovarian cancer.
Copyright © 2008 Roberta B. Ness et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Ovarian cancer is an often fatal disease with an uncertain
etiology. We suggested that pelvic inﬂammation may play
a role in the development of ovarian cancer [1]. PID has
been linked to ovarian cancer risk in some [2, 3]b u tn o ta l l
[4] studies. However, PID is poorly recalled in retrospective
studies.
One quarter to three quarters of proven cases of PID are
caused by Neisseria gonorrhoeae or Chlamydia trachomatis
ascending into the upper genital tract to inﬂame the
endometrium, tubes, and ovarian epithelium [5]. Of the two
pathogens, C. trachomatis is the most common in American
women [6].
Chlamydia serology is a relatively speciﬁc marker of past
chlamydial PID, particularly of more severe infections [7].
Its sensitivity is not complete; of women with chlamydial
PID, about 60% will have antibodies to C. trachomatis [8]
and among women with tubal factor infertility, a similar
proportion will have IgG titers to chlamydia [9].
We previously reported pilot results from a population-
based case-control study (117 cases and 170 controls) of
ovarian cancer showing that ovarian cancer was signiﬁcantly
associated with high IgG antibody titers to chlamydia [10].
The purpose of the present study was to attempt to replicate
this ﬁnding in a larger population-based case-control study
of ovarian cancer.
2. MATERIALS AND METHODS
Subjects for this serologic analysis were part of a population-
based case-control study conducted in a contiguous region
comprising Western Pennsylvania, Eastern Ohio, and South-
western New York State. Cases were residents of this
geographic region with histologically conﬁrmed, primary,
epithelial ovarian, fallopian tube, or peritoneal cancer
diagnosed between February 2003 and July 2006. Both
invasive and borderline tumors were included. Women were
referred from hospital tumor registries, clinical practices, or
pathology databases and contacted with the permission of2 Infectious Diseases in Obstetrics and Gynecology
Table 1: Frequencies of demographic and reproductive characteristics by case/control status.
Variable Case subjects no. (%) Control subjects no. (%) χ2 (P value)
Age group, years
24–49 135 (25.9) 204 (26.6)
9.29 (.026) 50–56 111 (21.3) 208 (27.2)
57–66 129 (24.8) 187 (24.4)
≥67 146 (28.0) 167 (21.8)
Ethnic group
White 495 (95.0) 736 (96.1)
1.14 (.57) Black 19 (3.6) 20 (2.6)
Other 7 (1.3) 10 (1.3)
Education
Less than high school 46 (8.8) 37 (4.8)
13.56 (.001) High school 180 (34.5) 229 (29.9)
Posthigh school 295 (56.6) 500 (65.3)
Family history of ovarian
cancer
No 487 (95.3) 731 (97.3) 3.74 (.053)
Yes 24 (4.7) 20 (2.7)
Live births
None 124 (23.8) 104 (13.6) 22.23 (.000)
Any 397 (76.2) 662 (86.4)
Tubal ligation
No 389 (78.3) 490 (65.0) 25.3 (.000)
Yes 108 (21.7) 264 (35.0)
Oral Contraception, years
0 223 (42.8) 214 (27.9)
40.02 (.000) <1–4 205 (39.3) 321 (41.9)
5–9 59 (11.3) 134 (17.5)
≥10 34 (6.5) 97 (12.7)
Menopausal status
Premenopausal 142 (30.4) 194 (29.9) .028 (.87)
Postmenopausal 325 (69.6) 454 (70.1)
Self-report PID
No 515 (98.8) 759 (99.1) .18 (.68)
Yes 6 (1.2) 7 (0.9)
Self-report gonococcal or
chlamydial cervicitis
No 502 (96.4) 736 (96.1) .062 (.80)
Yes 19 (3.6) 30 (3.9)
their gynecologists. Eligible women were at least 25 years of
age and within 9 months of initial diagnosis.
Controls consisted of women at least age 25 who lived
in telephone exchanges wherein cases resided. Random digit
dialing was used to identify age-eligible women, and these
were further screened by the study team to ensure that
they had not had a previous oophorectomy or diagnosis
of ovarian cancer. Eligible women were then invited to
participate. Potential controls were frequency matched by
5-year age group and telephone exchange to cases in an
approximately 2:1 ratio.
Women were interviewed in their homes by trained
interviewers. The questionnaire included a reproductive and
gynecological history, a contraceptive history, a medical his-
tory, a family history, and information on lifestyle practices.
We were able to draw blood on 92.5% of the interviewed
cases and 84.4% of the interviewed controls. Blood samples
were processed within 2 hours of collection by a laboratory
technician. For this analysis, we selected the ﬁrst 521
cases and 766 controls with complete questionnaires, tumor
registry (e.g., histology) information, and adequate serum
samples.R o b e r t aB .N e s se ta l . 3
Table 2: Frequencies and adjusted odds ratios (ORs) and 95%
conﬁdence intervals (CIs) for chlamydial elementary bodies optical
density (OD) units, in cases and controls, categorized by previously
deﬁned cut points. (ORs were adjusted for age, education, family
history of ovarian cancer, tubal ligation, nulliparity/any parity, and








<0.10 248 342 1.0
0.10–0.199 138 173 1.1 (0.8–1.5)
0.20–0.399 73 113 0.9 (0.6–1.2)
≥0.40 62 138 0.6 (0.4–0.9)
Table 3: Frequencies and adjusted odds ratios (ORs) and 95%
conﬁdence intervals (CIs) for chlamydial elementary bodies, cat-
egorized by quartiles, in case and control subjects. (ORs were
adjusted for age, education, family history of ovarian cancer, tubal








<0.06 133 189 1.0
0.06–0.11 133 189 1.1 (0.8–1.5)
0.11–0.24 146 176 1.2 (0.9–1.7)
≥0.25 109 212 0.7 (0.5–1.1)
2.1. Serologictesting
Serologic testing for IgG antibodies to serovar D of C.
trachomatis elementary bodies (EBs), the extracellular form
of the chlamydia bacteria, was conducted in the reference
laboratory of one of the authors (RB) using an ELISA
technique. Final readings are based on a mean of duplicate
runs. All assays were conducted by personnel masked to
case/control status. The intra-assay coeﬃcient of variation
for chlamydia antibodies was 0.06, representing excellent
intra-assay replication. Among masked replicates admixed
intothetestset,Pearsoncorrelationcoeﬃcientswere0.90for
chlamydia, again representing excellent interassay variability.
2.2. Statisticalanalysis
Each of the antibody levels tested was measured in optical
density (OD) units (range 0.0–0.4+). We log transformed
all OD units to reduce skewing when considering these as
continuous measures and categorized OD units into neat
whole number categories when considering these as discrete
measures. These cut points corresponded to those in our
published pilot study [10]. Odds ratios, with corresponding
95 percent conﬁdence intervals, were calculated as the
primary measure of eﬀect size. Odd ratios were adjusted
in unconditional logistic regression models for any residual
eﬀect of age and for family history of ovarian cancer in
any ﬁrst degree relative (yes/no), tubal ligation (yes/no),
nulliparity versus any parity, years of oral contraception
(continuous), and education (<high school/high school or
equivalent/>high school). In secondary analyses, we divided
serologic titers by quartiles; we also performed secondary
analysis limiting our evaluation to only women with invasive
ovarian cancer. We also stratiﬁed by age to assess cohort and
age eﬀects. Chlamydial infections typically occur in younger
women. Older women may have time-related diminished
antibody titers.
3. RESULTS
About one quarter of women were younger than the age of
50 and half were age 50 to 65 (see Table 1). Only about 1% of
women reported having PID and 4% reported having gon-
orrhea or chlamydia. The well-established protection against
ovarian cancer aﬀorded by oral contraception, pregnancies,
and tubal ligation, and the risk from a family history of
ovarian cancer were demonstrated here.
After adjustment for possible confounding factors and
based on our previous antibody titer cut points [10], women
withovariancancerwerelesslikelythancontrolstohavehigh
chlamydia EB OD unit titers (≥0.40 versus <0.10) (OR 0.6,
95% CI 0.4–0.9; test for trend P = .001) (see Table 2). We
then recategorized chlamydia EB OD units as quartiles based
on the distribution of antibody values among controls (see
Table 3). After adjustment for covariates, the highest quartile
of chlamydia EB antibodies was inversely nonsigniﬁcantly
associated with ovarian cancer (OR 0.7, 95% conﬁdence
interval 0.5–1.1).
In age-stratiﬁed analyses, we continued to ﬁnd the
chlamydia antibodies that reduced ovarian cancer risk (see
Table 4). Results were also similar in analyses limited to
invasive ovarian cancer; the risk for ovarian cancer among
women in the highest quartile of chlamydia EB antibodies
versus the lowest was 0.6 (0.4–0.9, test for trend P = .021).
4. DISCUSSION
We found that women with ovarian cancer were less likely
to have high levels of IgG to C. trachomatis serovar D EBs.
Our data are inconsistent with our previously published
pilot results [10] which showed higher serologic titers for C.
trachomatis among ovarian cancer patients.
Our current ﬁnding is the reverse of the link between
chlamydia and ovarian cancer in our previous analysis [10].
This is diﬃcult to explain. The same laboratory conducted
serologic analyses using similar methods for both studies. A
population-based case-control method was used to recruit
women into both ovarian cancer case-control studies.
Explanations for a lack of association include the long
period between exposure to chlamydia (in the reproductive
period) and blood collection (generally after the age of 50)
in our population. If titers fall signiﬁcantly over time, they
m a yh a v eb e c o m eu n d e t e c t a b l ei ns o m ew o m e n .D a t af r o ma
Dutch study suggested that 18% of women had a decline of
twofold in chlamydia titers over four years [11]. However in
our own data, over 5–7 years of followup, women with the4 Infectious Diseases in Obstetrics and Gynecology
Table 4: Frequencies and adjusted odds ratios (ORs) and 95% conﬁdence intervals (CIs) for chlamydial elementary bodies optical-density
(OD) units, in case and control subjects stratiﬁed by age.
OD units Case subjects Control subjects OR (95% CI)
Age 24–49
<0.10 69 82 1.0
0.10–0.199 32 42 0.9 (0.5–1.6)
0.20–0.399 18 37 0.6 (0.3–1.1)
≥0.40 16 43 0.4 (0.2–0.9)
Trend = .007
Age 50–56
<0.10 55 103 1.0
0.10–0.199 22 47 0.9 (0.5–1.6)
0.20–0.399 15 20 1.4 (0.7–3.0)
≥0.40 19 38 0.9 (0.5–1.8)
Trend = .908
Age 57–66
<0.10 58 88 1.0
0.10–0.199 41 38 1.6 (0.9–2.8)
0.20–0.399 19 31 0.9 (0.5–1.8)
≥0.40 11 30 0.6 (0.3–1.2)
Trend = .227
Age ≥67
<0.10 66 69 1.0
0.10–0.199 43 46 1.0 (0.6–1.7)
0.20–0.399 21 25 0.9 (0.4–1.7)
≥0.40 16 27 0.6 (0.3–1.3)
Trend = .217
highest antibody titers rarely moved to the lowest tertile over
time [12].
Another explanation is the lack of sensitivity of antich-
lamydial antibody serologic testing. Only about 60% of
women with PID develop detectable serology, and the test
does not detect gonorrhea, another cause of PID. This lack of
sensitivity would have resulted in erroneously missing some
women with prior PID and would have resulted in an odds
ratio biased toward the null. Moreover, it is possible that
ovarian cancer itself or its treatment might acutely reduce
chlamydia titers, and therefore mask an association.
Strengths of this study include the population-based
ascertainment of cases and controls, the standardized collec-
tionandstorageofbloods,themeasurementofchlamydiaEB
antibodiesatareference,researchlaboratory,withlaboratory
personnel masked to case-control status, and evidence
of an independent eﬀect after adjustment for potentially
confounding factors.
In summary, our ﬁndings do not support previous
evidence of a link between chronic persistent chlamydia
infection, the most common cause of PID, and risk for
ovarian cancer.
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